June 17, 2008

Vol. 5 No. 118

View Archived Issues

Sign Up Now

FDA to Classify Mercury Fillings by Summer 2009

As part of a settlement in a lawsuit filed by Moms Against Mercury, the FDA has agreed to classify a controversial mercury-containing cavity filler by July 28, 2009. Read More

Study: Scanner Detects Smallest Cancers Better Than MRI

Naviscan PET Systems reported clinical data using the positron emission mammography (PEM) Flex Solo II scanner in breast cancer management. Read More

BioMedical Enterprises Launches Barbed Nitinol Implant

BioMedical Enterprises is launching its Barbed OSStaple (BOSS), a nitinol implant designed for internal fixation of bones. Read More

Bertarelli Steers Course for Euromedic

Ernesto Bertarelli, the Swiss-Italian biotech billionaire, returned to the front line of business as his new  $1.5 billion healthcare fund joined with Merrill Lynch to buy Euromedic, the Hungary-based medical diagnostics and dialysis group. Read More

Test Used to Spot Pre-Diabetes in Kids May Miss Two Out of Three

Obese children at risk of developing Type 2 diabetes may not be getting the news soon enough to take preventive action because the test used to gauge their condition is not sensitive enough, a new study suggests. Read More

Maui Company Banks on High Demand for New Optical Device

A high-technology company on Maui plans to double its work force as it manufactures and markets a new device for the pharmaceutical industry. Read More

AVI BioPharma, Global Therapeutics Advance in Cardiovascular Program

AVI BioPharma, Inc. announced that its partner in its cardiovascular program, Global Therapeutics, the cardiology unit of Cook Medical, has received CE Mark approval for a new cobalt chromium bare metal stent. Read More

Microarray Chip Predicts Impairment, Remission in Rheumatoid Arthritis

A new DNA microarray chip can predict severe disability and remission in patients with rheumatoid arthritis (RA), as presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France. Read More

Hypertension Treatment Device Further Validated in New Studies

InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange, announced the findings of new studies and analysis highlighting RESPeRATE — the only medical device cleared by the FDA and CE-approved for the treatment of hypertension. Read More